Home › Ovarian Cancer › NCT06436248
Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer
Who can join
Ages 25 and older · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Female, age 25 or older (given that women under this age are not generally recommended to receive BRCA1/2 genetic testing) * Completed full sequence or targeted genetic testing with a clinically confirmed BRCA1 or BRCA2 deleterious mutation identified. * English-fluent; the surveys and interviews were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys. Exclusion Criteria: * Previous receipt of any prophylactic oophorectomy * Personal history of ovarian cancer * Major psychiatric illness or cognitive impairment that in the judgment of the study investigators would preclude study participation. * Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.
About the study
The overall goal of the Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer (PROMISE) study is to better understand how women may incorporate both polygenic risk score (PRS) and novel early detection strategies in their decisions regarding cancer screening and risk reducing surgery. This study will conduct qualitative interviews to better understand women's attitudes regarding polygenic risk score (PRS) and early detection assays.
Sponsor: Abramson Cancer Center at Penn Medicine · Participants: 24 · Started: Jul 1, 2024
Contact the study team
- Jamie Brower, MS · Phone: 215-662-7245
Official record on ClinicalTrials.gov — NCT06436248
Locations in the U.S.
| Pennsylvania | Abramson Cancer Center, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.